Novel Heterocyclic Dpp-4 Inhibitors for the Treatment of Type 2 Diabetes.
Sutton, J.M., Clark, D.E., Dunsdon, S.J., Fenton, G., Fillmore, A., Harris, N.V., Higgs, C., Hurley, C.A., Krintel, S.L., Mackenzie, R.E., Duttaroy, A., Gangl, E., Maniara, W., Sedrani, R., Namoto, K., Ostermann, N., Gerhartz, B., Sirockin, F., Trappe, J., Hassiepen, U., Baeschlin, D.K.(2012) Bioorg Med Chem Lett 22: 1464
- PubMed: 22177783 
- DOI: 10.1016/j.bmcl.2011.11.054
- Primary Citation of Related Structures:  
4A5S - PubMed Abstract: 
Novel deazaxanthine-based DPP-4 inhibitors have been identified that are potent (IC(50) <10nM) and highly selective versus other dipeptidyl peptidases. Their synthesis and SAR are reported, along with initial efforts to improve the PK profile through dec ...